NCT03148691View on ClinicalTrials.gov

A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis

PHASE2CompletedINTERVENTIONAL
Enrollment

253

Participants

Timeline

Start Date

May 17, 2017

Primary Completion Date

February 28, 2018

Study Completion Date

April 3, 2018

Conditions
Seborrheic Keratosis
Interventions
DRUG

A-101

Topical Solution

Trial Locations (9)

10003

Union Square Laser Dermatology, New York

19034

Philadelphia Institute - Dermatology, Fort Washington

19104

Perelman Center for Advanced Medicine, Philadelphia

20037

Center for Dermatology and Dermatologic Surgery, Washington D.C.

29607

Greenville Dermatology, Greenville

30263

MedaPhase, Inc, Newnan

33137

Baumann Research Institute, Miami

37922

The Skin Wellness Center, PC Clinical Research Division, Knoxville

78759

DermResearch Inc, Austin

Sponsors
All Listed Sponsors
lead

Aclaris Therapeutics, Inc.

INDUSTRY

NCT03148691 - A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis | Biotech Hunter | Biotech Hunter